Cancer Vaccine


Also found in: Wikipedia.
A vaccine that either prevents infections with cancer-causing viruses—e.g., HPV—treats existing cancer or prevents the development of cancer in certain high risk individuals. The first effective cancer vaccine is that for preventing cervical cancer. Dendreon Corp’s Provenge, a vaccine for advanced prostate cancer, was approved by the FDA in 2010 and adds about 4 months of life to the average person’s lifespan, at an estimated cost of $100,000. Other CV candidates include peptides, proteins, whole cancer cells, dendritic cells, gangliosides, heat-shock proteins, viral and bacterial vectors, and oligonucleotides
References in periodicals archive ?
com/research/t7lvc3/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering.
No therapeutic cancer vaccine has received approval in any of the seven major pharmaceutical markets, despite extensive research efforts.
Overall, the report uncovers the likely future directions in the cancer vaccine field and the potential challenges facing this move.
Analytical Tool - Cancer Vaccines" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine drug development.
Bharat Book Bureau presents Cancer Vaccine Partnering Terms and Agreements.
Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:
com/research/eb249c/cancer_vaccine_dev) has announced the addition of the "Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker" report to their offering.
24, 2014 /PRNewswire/ -- The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
Although the cancer vaccine industry has remained historically undervalued due to its failures, optimism surrounds the industry as proponents of this technology have persistently pursued investigations to demonstrate the clinical efficacy of cancer vaccines.
Cancer vaccine development has changed from a small-scale academic enterprise in to an applied science requiring a large clinical research infrastructure.
What requirements must a cancer vaccine satisfy to achieve significant clinical response?

Full browser ?